A snapshot Into Global CBD Insights Trends and Market Size
The global Cannabidiol (CBD) market is projected to grow at a compound annual growth rate of 125% from 2019 to 2026. The robust growth stems from growing awareness of CBD health benefits as well as the opening up of the market around the world. An increase in the number of countries that have legalized the use of CBD for its health claims has helped foster further growth, making CBD a buzzing market phenomenon.
CBD Insights
CBD is a compound extracted from hemp and marijuana for its medicinal and therapeutic properties. The compound has emerged as a remedy for addressing various medical conditions such as inflammation, pain as well as sleep disorders. CBD infused products such as cannabis oil, beauty and skincare products, gummies, and dog treats have since cropped up as manufactures continue to explore ways of leveraging CBD properties. In recent years, there has been a spike in demand for cannabidiol in pharmaceutical formulations, by virtue of the compound’s comforting properties. Likewise, hemp production has continued to edge higher as growers and producers look to take advantage of the growing market appeal. Strong demand for CBD skincare products made up of moisturizers creams, cleaners, oils and sun creams continued to trigger strong demand for CBD. The use of CBD in beauty products has gathered momentum in recent years owing to the compound’s anti-inflammatory and antioxidant properties.
Distribution Channels
Considering the fact that cannabidiol is still a controlled substance in many jurisdictions around the world, wholesalers and retailers must have a license from relevant authorities to distribute it. In countries where CBD is legal for medicinal purposes, hospitals and pharmacies have a leeway to prescribe CBD products without too many restrictions. Likewise, hospitals and pharmacies account for the biggest share when it comes to CBD distribution around the world. Retail Pharmacies come a distant second specializing mainly in offering CBD infused personal care products, food items, and medicines. Online stores such as Pure CBD Vapors, CBD Outlet Online, and Discover CBD offer multiple CBD-infused branded products and edibles as well as wax forms. CBD Regional Insights The U.S and Canada continue to lead the way, given the size of their CBD market. North America stands out in part because of friendly regulatory frameworks. A number of states in the U.S have already legalized the recreational and medicinal use of cannabis; Canada having legalized cannabis at the federal level. The Americas accounted for 78% of the global CBD market in 2018 at $2.4 billion, with Europe coming a distant second with a market value of $358 million. The beverage segment of the CBD market remains the biggest accounting for 51% of the total market valued at about $1.6 billion. This segment is projected to soar 127% by 2026.
While cannabis has remained a banned substance in most countries, some country’s attitudes are slowly changing. Asia for instance, presents an enormous untapped market opportunity. The country is considered an attractive region for laboratory proficiency owning to the territories’ large base of manufacturers as well as research laboratories.
Growing CBD Investments
Sensing a window of opportunity, a number of companies have jumped on the CBD bandwagon, creating a vast assortment of products around Cannabidiol and its byproducts. Veritas Farms, Inc. (OTCQB: VFRM), a vertically integrated agribusiness, has invested vast sums of money on the production of a full-spectrum of CBD products. The company has recently unveiled a line of natural hemp oil products that contain CBD and intend to continue to add to their assortment in the near future. Dubbed as the leader in hemp extraction products, Charlotte’s Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) has expanded its research initiative with The Center for Discovery in New York as it seeks to develop hemp genetics. The company’s breeding program is spearheading the development of superior CBD varieties to support the efforts of local farmers. Medical cannabis firm EXMceuticals Inc. (CNSX: EXM) is another company that has set sights on the CBD landscape focusing on North America as well as Europe. The company has already secured a cannabis research and development license from the Portuguese National Authority of Medicines and Health products to lead the way in European CBD circulation and, ultimately, worldwide distribution.
Bottom line
Increased hemp production fueling the rising demand for cannabidiol rich hemp biomass should continue to bolster CBD market growth. Likewise, increased adoption of refined CBD products coupled with the legalization of medical marijuana should drive demand for CBD products worldwide. Furthermore, companies are beginning to adopt new strategies and plunging into strategic mergers and acquisitions to strengthen their CBD production capacities. As progressive CBD companies move to expand their presence in the industry, the global CBD market size should continue to clock new heights globally.
Ruchi Gupta is financial journalist, specializing in small-cap companies mainly in the cannabis space. Disclosure: Ruchi Gupta works for Momentum PR, which represents EXMceuticals on the public relations front.
This Is Why Grown Rogue International Inc. (CNSX: GRIN) Appears Undervalued
Grown Rogue International Inc. (CNSX: GRIN) share price is yet to paint an accurate picture of the company’s tremendous potential amidst improving fundamentals. Investor sentiments in the stock did take a hit if price action in the first half of the year is anything to go by. Wild price swings saw the stock rally by more than 50% before tumbling to all-time lows.
The plunge came as a surprise as it came at a time when the broader cannabis sector was flying high. In addition, the company has been on an impressive run on the execution of its core business affirming growth metrics and the need for a higher valuation in the market.
Sales Growth
Grown Rogue is enjoying its best run when it comes to sales growth. The company reported a record-breaking quarter depicted by 388% YoYo growth in sales that came in at $834,309. At the end of the quarter, the company projected continued growth throughout the year, relying on expansion plans to key cannabis markets of California, Oregon, and Michigan.
The Company did meet its promise of robust growth on reporting a 125% quarter over quarter increase in sales in Q2 that came in at $1.9 million. Sales growth is indicative of brand strength as well as distribution reach, as the company continues to expand its wings into new markets. The company has since grown from controlling just three cannabis licenses to 22 licenses further affirming its multi-state operations.
“To have gained this brand recognition and sales traction, in what is arguably the world’s most competitive legalized cannabis market, bodes very well for our expansion into California and particularly the newly legalized market in Michigan,” said CEO Obie Strickler.
Sales growth looks set to be the order of the day as the company has expanded its footprint into Michigan as part of its growth strategy. Michigan becomes the third state from which the company will operate in addition to Oregon and California.
The expansion should reduce the company’s reliance on one market for growth. It should also shield it from the effects of a downturn in one market.
Gross margins have also shown signs of improvement helped by robust growth in revenues. Gross margin in the recent quarter improved to $0.4 million, a 20% increase. Margins are likely to continue improving as cannabis prices in Oregon show signs of edging higher as demand continues to outpace supply.
Organic Growth
Grown Rogue has also underscored its push for growth at all cost. The acquisition of Decibel Farms affirms push for inorganic growth even as the company continues to refine its internal operations to accelerate organic growth.
The acquisition of Decibel Farms marks an important milestone in the company’s growth strategy. With the acquisition, the company gains access to a valuable asset poised to strengthen its cannabis cultivation and production capacity further.
According to the Chief Executive Officer, Decibel Farms will bolster Grown Rogue manufacturing capacity in Oregon where demand for cannabis products is on the rise. Production capacity could reach highs of 5,400kg by the end of the year with the scaling of cultivation operations.
“We believe that licenses, assets, and operations are of little value without an experienced team that knows how to cultivate quality cannabis products at scale and build meaningful brands. Our team has been building these core competencies for the past 3 years,” added Jacques Habra, Chief Strategy Officer.
Demand for branded products continues to exceed internal production; one of the reasons the company is turning to acquisition to ramp up capacity.
Grown Rogue Price Analysis
While Grown Rogue has lost a significant amount of market value over the past six months, price action activity indicates potential to bounce back from all-time lows. The C$0.20 mark has since emerged as a crucial support level from where bulls appear to be jostling for positions consequently fuelling a bullish momentum.
Given the descending long-term bear trend and the fact that bears appear to be in control, the stock might have to rally and take out the C$0.24 resistance level, for the short-term momentum to turn bullish. A rally followed by a close above the C$0.24 mark could arouse buying pressure from buyers who have been on the fence.
https://ca.finance.yahoo.com/news/grown-rogue-reports-388-growth-111100202.html
https://ca.finance.yahoo.com/news/grown-rogue-announces-proposed-acquisition-124100831.html
https://ca.finance.yahoo.com/news/grown-rogue-second-quarter-revenue-123800178.html
- Published in Cannabis, CBD, Grown Rogue, Marijuana
GROWPACKER – the next Amazon of cannabis?
GROWPACKER; THE NEXT AMAZON OF CANNABIS?
What could Amazon possibly offer to make them even more successful? Imagine they offered the manufacturing, branding, packaging and total distribution of every one of their client’s products.
Well that’s what California based GrowPacker does; except they do it for anything and everything related to the cannabis industry. With regards to everything I mean; non-alcoholic beverages, carbonated and non-carbonated beverages, water, candies, chocolate bars, brownies, cookies, creams, lotions, massage oils, vape oils, pre-rolls, flower and the list goes on…
Growpacker clients provide them with their cannabis and preferred product parameters, including product specs and with that information Growpacker turns it into a finished ingestible and edible product. Because let’s face it, if your still invested in cannabis stocks that don’t produce eatables, start smoking your profits away because you missed the boat.
On top of converting your THC and CBD into anything infused, Growpacker will take care of formulations, lab testing, packaging and; even the total distribution and transportation of your product. They have a turn key formula with all the required licenses to boot! And to make this even more delicious, the competitors are far behind. Growpacker was one of the first to begin this process and therefore have acquired all, I mean all, the necessary licenses to make this a growers dream come true. Currently Growpacker has +450 clients in the pipeline and nearly 100 that have started the on-boarding process for production with upwards of 10 inquires per day. If only all start-ups could be so fortunate…
Another satisfying point about Growpacker is that they do what they say. By the end of 2018 they said that they would have all their licences and they did. They also said that they are working on a high-profile brand relationship with THC infused beer start-up, Ceria Beverages Company, and it was solidified.
Speaking of Ceria, let’s look at the advisory board and shareholders of Growpacker. Keith Villa, the original founding member of Blue Moon Brewery, America’s #1 craft beer with annual revenue exceeding $250M and brand value of over $1B now owned and operated by MillerCoors, is a special advisor and shareholder to the company. He is also the one spearheading Ceria.
Furthermore, the special advisory board is made up of InterContinental Beverage Capital; (IBC) founders Joe Messina, Stephen F. Horgan and Doug Christoph who have all held top executive positions at Coca Cola and MillerCoors. (IBC) is involved in serving financial and operational planning, debt restructuring, investment, re-branding, business performance, revenue growth and profitability. These three powerhouses make it clear that Growpacker is starting on a solid business foundation.
And if this weren’t enough, Jon Cooper founding member of Ebbu Inc. a U.S hemp research company recently acquired by Canopy Growth Corporation for $429M USD is also a special advisor and shareholder. He brings everything research and development on the hemp platform to push the boundaries of cannabis tech.
Now if this is not a formula for success, I don’t know what is. Combining the turn key production and distribution formula with some of the most successful people in business along with a company who is far ahead of its competition, feels as comfortable a stock pick as a good old THC infused Ceria beer! Watch out Amazon, here comes Growpacker.
About Growpacker
Growpacker is a fully-licensed cannabis co-packing and bottling company that operates in California, now the worlds fifth largest economy and Americas largest consumer market. Taking a bifurcated approach on the industry, Growpacker will have the ability to manufacture products for both the regulated cannabis market (dispensaries) as well as the open market for products that are CBD only (grocery, convenience store, etc). They have proprietary THC & CBD infusion technologies, allowing them to design and manufacture the most premium cannabis-infused products on the market, including both water and oil-based products.
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency, representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian-listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies, through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of Growpacker
—
Isabelle Arsenault
Media Relations
MomentumPR
p:+1.450.332.6939 m: +1.514.816.2611
w:www.momentumpr.com e: isabelle@momentumpr.com
- Published in Blog, Cannabis, growpacker, Marijuana, News Home, Technology
Canadian and US Cannabis Edibles and Consumer Products Market Set to Explode to US$ 4.1 Billion by 2022
Canopy Growth CEO Bruce Linton: “…related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol, sleep aids, appetite aids, sports drinks, medicines and pet care.”
If you can read them, the signs are there.
The marijuana edibles industry, that part of the recreational marijuana that be ingested as a candy, a chocolate, a candy bar or in a mixed drink or a beer is going to be huge and may very well eclipse that old standby the smokeable flower or bud.
During the summer ResearchAndMarkets predicted that the global cannabis infused edible products market would grow at an expected CAGR of 25.01% from 2018 to 2022. The infused beverage market would include CBD based
recovery drinks and tonics as well as potent THC infused beers.
An October 11, press release announcing a new report, “The Tasty Future of Cannabis Edibles,” by BDS Analytics and Arcview Research predicted that by 2022 the edibles market would exceed US$4.1 billion, up from US$1.5 billion, for the Canadian and US market in 2018.
A June article in Forbes ran the headline “New Data Shows that Smoking Marijuana is a Dying Trend.” The data it references is the 2018 Deloitte report on the emerging Canadian marijuana market and the Forbes story says, A recent analysis from Deloitte shows that “smokable marijuana” in the northern nation will generate in upwards of $5 billion in 2019. But the edibles sector is predicted to hit somewhere between $12 and $22 billion by the time the market is in full swing.”
According to the BDS and Arcview report the THC infused candy and chocolate market segment took the lion’s share of the US market at 60%. The press release quotes Troy Dayton the CEO of ArcView Market Research: “Established big brand food and beverage companies are beginning to take notice of the cannabis edibles market and this is likely just the tip of the iceberg.”
If anyone doubts that edibles and beverages are the next big thing they should remember Constellation Brands $4 billion investment in Canopy Growth. Of course if that doesn’t convince you then there is also the partnering dance between Coca-Cola and Aurora that somehow didn’t get off the ground. Just how big the market is going to be is still up for grabs.
In a video on TheStreet.com, Canopy Growth CEO Bruce Linton claimed that related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol sleep aids appetite aids sports drinks and medicines and pet care.
If you think the $500 billion figure was a bit too high Constellation Brands COO Bill Newlands predicted that the legal cannabis product market would hit $200 billion plus. “Our View is that in the next ten plus years, this is going to be a $200 billion business worldwide. And some would argue that’s understating the case.”
It’s not difficult to see why the edibles market segment is going to take off.
Smoking is, after all, bad for you. The more difficult question to answer maybe how to profit from what will be a long term market build out and development, one that, ResearchAndMarkets.com has predicted will grow at an astonishing rate of 25.91% CAGR for the years 2018-2022. At the moment almost every major Canadian marijuana company has either a beverage in development or edibles underway in a test kitchen. Edibles and beverages are made from oils and compounds removed from the plants by volatile or non-volatile extraction methods. One way of investing in this developing market lies in investing in those companies that are extracting THC and CBDs from marijuana and then selling it business to business for use in either medical marijuana or as food grade marijuana.
North Bud Farms (CSE: NBUD) is building out its 95 acre site in Low Quebec where it is in within 10 km of a major hydro power plant. Construction is scheduled to be finished Q1 2019 and at the moment is on time and within budget.
The company is also in the process of applying of for a production license under the Access to Cannabis for Medical Purposes Regulation (ACMPR). North Bud has cleverly tagged itself as Marijuana 2.0, in reference to the second wave of legal marijuana slated for October 2019, when the edibles and infused beverage market will be open for business. The company’s strategy is to supply two underserved markets by producing and selling certified pharmaceutical grade cannabis and GMP standard raw cannabis for the food and beverage industry. The company also intends to develop and market new products.
To that end it has recently signed a number of agreements that will help turn its words into action. On September 27, 2018 the company announced that it had signed an agreement with American firm Made By Science to license its cannabinoid infusion technology for food and beverage platform.
On October 17, 2018 North Bud announced that it had created a distribution company, “1017,” so named to commemorate the date of marijuana legalization Canada, and signed a letter of intent to acquire Janey’s, one of the six licensed marijuana accessory distributers in Ontario. Janey’s is also engaged in marijuana product development. North Bud intends to develop multiple products over a variety of product segments under the 1017 brand.
As of November 15, 2018 North Bud Farms, (CSE: NBUD) was trading at $0.25.
Given the predicted explosion in the marijuana consumables and edibles market laying a bet or two on companies in that field makes sense and one such company that bears keeping an eye on is Arev Brands International (CSE: AREV), formally Arev Nutrition Sciences. Arev originally saw life as a developer and marketer of coconut oil based health products. It is focussed on two distinct market sectors, consumer products and manufacturing as an ingredients supplier. Along the way the company also developed a unique extraction technology and this is where they fit into the consumables market segment.
In a press release on Bloomberg the company announced that it had reached a major milestone in extraction development with its partner Alternative Extracts Inc. Using its proprietary extraction system Arev has developed a
system that preserves flavour and aroma and which in the case of beverages may lengthen shelf life. It intends to manufacture finished oil products with proprietary strains bred to specifically address key health issues: anxiety, pain management, central nervous system disorders, insomnia and libido.
Arev also has an exclusive distribution agreement with the award winning full line of BARE Topical products.
In September 2018 the company completed its acquisition of BC Bud Depot. BCBD has one of the world’s largest cannabis seed banks. Over the last 14 years BCBD has won over 40 awards and was the first Canadian company to win an international award with “BC God Bud,” now Canada’s most award winning strain of all time.
On November 15, 2018 AREV was trading at $0.365.
This blog should not be construed as investment advice. Every investor is obligated to perform his or her own due diligence. In the interests of transparency Arev and North Bud Farms are both Momentum Public Relations clients.
- Published in AREV Nutrition Sciences, Blog, Marijuana, Medical Marijuana, NorthBud
Relevium Creates Cannabis Brands for North-American Market
Momentum Public Relations
Press Release: April 26
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of its two first cannabis brands, LeefyLyfe and Biocannabix offering cannabis products in the North-American and European markets. LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health Corporation (the “Subsidiary” or “BHC”).
Highlights
- Biocannabix® will target the Canadian market pursuant to ACMPR regulations
- LeefyLyfe® will target CBD sales outside of Canada in full compliance with local legal and regulatory framework
- All resources being pooled to fast track the company’s positioning in the cannabis space
Aurelio Useche, CEO of Relevium stated: “We believe the organizations that build credible, trusted and recognizable brands in the CBD market will be the winners in this already fragmented space. At RLV, we are leveraging our current branding and online abilities in combination with all the resources at our disposal internally and externally to position the Company in the consumer products cannabis space.” Mr. Useche continued: “From formulation to branding and e-retail, we will be able to monetize CBD and CBG based consumer products outside of the Canadian market while the application for an ACMPR license for Canada is being worked on. We believe that this approach provides the best balance of short and mid-term ROI and an ideal risk ratio.”
Biocannabix
Relevium will be building the Biocannabix® brand in for the Canadian market and focus the brand architecture towards the medical and health markets. The Company has secured http://biocannabix.com/as the domain for the brand.
In order to gain access to the cannabis for medical purposes market and obtain the necessary licenses from Health Canada, including the ACMPR license, the Company has begun the process of evaluating locations in Quebec that could accommodate the operation. The Company has studied industry peers and believes that with the amount of data available it will be able to act swiftly and in a very cost-effective manner.
LeefyLyfe
Relevium will be building LeefyLyfe® as an elevated and trusted brand for the health-conscious consumer outside of Canada, with a focus on full spectrum hemp, CBD and CBG formulations aimed for lifestyle, health and wellness. The product offering targetsapplications ranging from pain relief and anti-inflammation to anxiety and sports performance. The Company has secured http://leefylyfe.com/ as the domain for the brand.
Relevium has already shortlisted production partners that would be able to meet stringent legal and compliance guidelines. All products being contemplated for the LeefyLyfe® brand will be derived from American grown, organic and non-genetically modified hemp.
The Company projects sales for LeefyLyfe® to commence in Summer in full compliance with rules, regulations and laws at the State and Federal levels.
Building a Brand Portfolio
In full alignment with the company’s business strategy, management is engaged in a process to secure branding licensing agreements and endorsement opportunities tailored for different consumer segments in this market. As opportunities arise, they will be subject to focus group and SWOT analysis in order to evaluate a proper risk/reward for the Company. The Company anticipates having a high-end premium or luxury brand offering in the spring or summer depending on a variety of factors.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel
Momentum Public Relations
Press Release: April 24
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.
Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.
About PPP001
On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
bob@tetrabiopharma.com
M: +1 514 817-2514
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement
Momentum Public Relations
Press Release: March 28 2018
Tetra Bio-Pharma Inc.(TBP:V), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,292,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,292,000. Each unit consists of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $1.30 per share for a period of thirty-six months expiring March 28th, 2021.
The Corporation intends to use the net proceeds of the Offering to advance its Phase 3 trial for PPP001 and other clinical trials, to effect the repayment of indebtedness, for the support of its commercial efforts and for general corporate and working capital purposes.
The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. Completion of the private placement remains subject to the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.
The securities described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The Corporation paid commissions in association with the financing of an aggregate of $275,800 in cash and the issuance of 275,800 finders’ warrants to GMP Richardson and IA Securities, exercisable at a price of $1.00 for a period of 24 months from closing. Each finders’ warrant is exercisable into a common share and common share purchase warrant, which is exercisable at a price of $1.30 per common share purchase warrant for a period of 24 months from the closing of the financing.
The TSX Venture Exchange Inc. has not approved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Tetra Bio Pharma
Canadian Companies Have Chance to Dominate Global Medical Cannabis Market.
Momentum Public Relations
Blog: March 21 2018
Tetra Bio-Pharma Receives FDA Orphan Drug Status for PPP001
Canadian Companies Have Chance to Dominate Global Medical Cannabis Market.
Grand View Research has predicted that the global medical marijuana market will reach US$55.8 billion by 2025.
When licensed medical marijuana producers first began to list on the Canadian stock exchanges they received sky high valuations.
Some analysts and producers looked beyond the domestic market and wondered if the legalization of marijuana in Canada would allow Canadian marijuana growers to take a dominant position in the global market as marijuana legalization rolled out around the world.
It now looks as if Canada stands a good chance to become a global leader in the development of cannabinoid-based drugs and the regulatory approvals that ensure their safety and efficacy.
The cannabinoid-based drug market is going to be huge. Grand View Research has predicted that the global medical marijuana market will reach US$55.8 billion by 2025.
A Bloomberg News story published in the Financial Post on December 28, 2017 explains why Canadian medical cannabis producers and drug companies are set to move onto the global stage.
The established use of medical cannabis in Canada and the legalization of recreational marijuana both play a part in this.
Canopy Growth CEO Bruce Linton was quoted in the story as saying that the theme for 2018 will be the globalization of medical cannabis. One of Canada’s first medical marijuana producers, Canopy already ships to Germany and has partnerships with companies in Australia, Spain and Jamaica.
In effect, Canada has first mover status on the international market and if domestic producers do the right things they stand a good chance of dominating the global market.
While medical cannabis is now being prescribed in a variety of jurisdictions, it is only being prescribed because of anecdotal evidence. There is no scientific proof that medical cannabis-based therapeutic treatments work. The pharmaceutical companies that succeed in providing regulatory approval backed by hard science stand to profit with a very large market share.
Canada is leading the way because while one might assume that research powerhouse the United States would be at the head of the line, American research is hamstrung by the fact that while legal in many states, it is not legal at the American federal level. This means that federal research funding is not available.
Against that backdrop Canadian biopharmaceutical research and development company Tetra Bio-Pharma, dedicated to becoming the first to prove the safety and efficacy of cannabis-based drugs, has received funding from the National Science and Research Council of Canada.
The company has already started a Phase 3 clinical study designed to prove the safety and efficacy of its flagship product, smokable PPP001, designed as a therapeutic treatment for chronic and cancer pain. The company believes that PPP001 will be on the market no later than 2019.
Canada’s ability to lead the international pack when it comes to the development of cannabis-based therapeutic drugs can be illustrated by two recent developments.
On March 14, 2018 Tetra Bio-Pharma announced that it had received “Orphan Drug Status” for PPP001, for the treatment of Complex Regional Pain Syndrome by the American FDA.
Orphan drug status is a designation used to encourage research into drugs for the treatment of rare diseases that affect only a small percentage of the population, 200,000. It provides a seven year marketing exclusivity for the orphan drug.
Tetra Bio-Pharma is a biopharmaceutical company dedicated to providing the science that will prove that medical cannabis-based drugs are safe and actually work.
Unless a dark horse dramatically emerges, Tetra Bio-Pharma will also be the first biopharmaceutical to be granted Health Canada and FDA approvals, which in return will grant the approved drugs a Drug Identification Number, DIN. DIN numbers allow the drug to be prescribed by doctors, sold by pharmacies and covered by insurance plans.
DIN numbers are the Holy Grail in pharmaceutical research. Once you have them your products are legal to market. Without a DIN number they can’t be sold.
Tetra has a pipeline of cannabis-based drugs under development and has recently created a veterinary division to create cannabis-based drugs for the lucrative cat and dog market.
The company has also just announced its first European foray with partner PS Innovations. PS Innovations manufactures Tetra’s trademarked RX Princeps Inhalation Device. Tetra announced on March 6, 2018 that PS Innovations will apply for CE Marking, a process that guaranties the product conforms to European regulations and can be sold in the European Economic Area where it will be listed as a Class 1 Medical Device.
Another indication that Canada stands a good chance of leading the medical cannabis world is the recent agreement between Sandoz Canada and licensed medical marijuana producer Tilray Inc. On March 19, 2018, Tilray announced that it had formed an exclusive partnership with Sandoz Canada to develop non-smokable cannabis-based therapeutic drugs delivered through gel caps or lotions.
Sandoz is owned by Novatis and the agreement represents big pharma’s first venture into developing cannabinoid-based therapeutic treatments.
Pascal Biosciences discovered certain cannabinoids that help our immune system kill tumor cells.
Canopy Growth also has a medical division that holds a number of patents. If Canada can develop the momentum that comes with first mover status there is a good chance that it can dominate the global medical cannabis market.
- Published in Blog
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
Momentum Public Relations
Press Release: March 20 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production. The HMMJ portfolio recently expanded to include ten new constituents, including Tetra.
“This is a very positive sign for our shareholders,” says Bernard Fortier, CEO of Tetra. “Having Horizons trusting us after completing a $11.5 million bought deal and in the process of a $ 4.5 million private placement is a strong message of confidence. Our clinical approach and pipe-line of products are unique and being added to this index reinforces the credibility of our approach to the financial community.”
HMMJ is an index (or passively managed) ETF, which seeks to replicate, to the extent possible, the performance of the North American Marijuana Index (the “Index”), net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry. The Index selects from a current universe of companies that have operations that may include one or more of biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses related to the marijuana industry.
More info on: https://www.horizonsetfs.com/news/Press-Release/Horizons-ETFs-Completes-Rebalance-of-its-Marijuana
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.
Momentum Public Relations
Press Release: March 19
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction”) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers”).
“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”
The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
- 1
- 2